Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

This study is currently recruiting participants.

Verified by Stanford University, November 2008

First Received: December 4, 2007 Last Updated: November 21, 2008 History of Changes

Sponsor:	Stanford University
Collaborator:	National Institutes of Health (NIH)
Information provided by:	Stanford University
ClinicalTrials.gov Identifier:	NCT00568490

Purpose

To correlate tumor oxygenation as measured by the Eppendorf electrode with the serum level of secreted proteins known to be induced by tumor hypoxia.

Condition	Intervention
Head and Neck Cancer Lip Neoplasms Lip Cancer Lung Cancer	Procedure: Eppendorf electrode measurements Procedure: Tumor biopsy Procedure: flabatomy

Study Type:	Observational
Study Design:	Prospective
Official Title:	Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

Resource links provided by NLM:

MedlinePlus related topics: Cancer Head and Neck Cancer Lung Cancer

U.S. FDA Resources

Further study details as provided by Stanford University:

Estimated Enrollment:	600
Study Start Date:	September 1998

Detailed Description:

The endpoints of the study are

To validate the prognostic significance of OPN in H&N and lung cancer patients and to monitor its level during active therapy and follow up for cancer surveillance.
To identify a gene and protein signature for hypoxia in H&N and lung cancer patients.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:Newly diagnosed patients with head and neck cancer who has tumor accessible to tumor oxygenation measurement with a microelectrode.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00568490

Locations

United States, California
Stanford University School of Medicine	Recruiting
Stanford, California, United States, 94305
Contact: Rachel Freiberg 650-725-4777 rachelf@stanford.edu
Contact: Cancer Clinical Trials Office (650) 498-7061
Principal Investigator: Quynh-Thu Le
Sub-Investigator: Amato Giaccia
Sub-Investigator: Richard L Goode
Sub-Investigator: Harlan Pinto
Sub-Investigator: Dr. Billy W. Loo Jr. M.D. Ph.D.

Sponsors and Collaborators

Stanford University

National Institutes of Health (NIH)

Investigators

Principal Investigator:

Quynh-Thu Le

Stanford University

More Information

No publications provided

Study ID Numbers:	SU-11052007-801, 15310; CA67166, 73995, ENT0016, NCT00568490
Study First Received:	December 4, 2007
Last Updated:	November 21, 2008
ClinicalTrials.gov Identifier:	NCT00568490 History of Changes
Health Authority:	United States: Food and Drug Administration; United States: Institutional Review Board

Additional relevant MeSH terms:

Mouth Diseases
Thoracic Neoplasms
Respiratory Tract Neoplasms
Lip Neoplasms
Mouth Neoplasms
Lip Diseases
Neoplasms

Neoplasms by Site
Respiratory Tract Diseases
Lung Neoplasms
Head and Neck Neoplasms
Lung Diseases
Stomatognathic Diseases

ClinicalTrials.gov processed this record on November 30, 2009